Pharma BD Deal Intelligence
Roche paid $125M for Mirus Bio's RNAi therapeutics arm in 2008 and abandoned the entire RNAi field just two years later, giving the assets, Madison site, and staff away to Arrowhead Research for a nominal $50,000 note plus minority equity.
Full analysis, sources & comparables →GenomeWeb described the deal as Roche 'expanding its stable of RNAi delivery technologies,' building on the prior Alnylam alliance to assemble the broadest…
Three-year postscript: Roche transferred the former Mirus Bio Madison, WI facility, DPC platform, ~40 scientists and IP to Arrowhead in 2011 after exiting RNAi…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
RNAi delivery, dynamic polyconjugate; transfection reagents spun out as Mirus Bio LLC
Roche paid $125M for Mirus Bio's RNAi therapeutics arm in 2008 and abandoned the entire RNAi field just two years later, giving the assets, Madison site, and staff away to Arrowhead Research for a nominal $50,000 note plus minority equity.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Mirus Bio Corporation (this deal) | 2008 | $125M | 10 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2008 deals · Roche Holding AG deals